Jiangsu Recbio Shareholders Approve Governance Overhaul and Board Changes

Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has provided an update.

Jiangsu Recbio Technology Co., Ltd. announced that shareholders at its 19 December 2025 extraordinary general meeting approved a series of corporate governance changes, including the abolishment of its Supervisory Board and related amendments to its Articles of Association, which took effect immediately. All six resolutions were passed by poll with 100% of votes cast in favor, covering the appointment of one new non-executive director, two new executive directors, and revisions to the company’s rules for managing connected transactions and the working procedures of independent non-executive directors. The strong support from shareholders, who represented about 44.7% of issued shares at the meeting, signals clear backing for the board’s move to streamline governance structures and refine oversight mechanisms, potentially affecting how the company manages related-party dealings and board independence going forward.

The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.

More about Jiangsu Recbio Technology Co., Ltd. Class H

Jiangsu Recbio Technology Co., Ltd. is a People’s Republic of China-incorporated joint stock company listed in Hong Kong, operating in the biopharmaceutical sector from its base in China Medical City, Taizhou, Jiangsu Province. The company’s shares comprise domestic shares, unlisted foreign shares and H shares, reflecting a capital structure aimed at both onshore and international investors.

Average Trading Volume: 42,323

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.63B

See more insights into 2179 stock on TipRanks’ Stock Analysis page.